Skip to main content
. 2022 Sep 23;19:45. doi: 10.1186/s12981-022-00470-3

Table 3.

Dose reduction and/or delay in patients with HIV and concomitant CRC according to antiviral regimens (n = 66)

DTG/3TC/TDF (group I) n = 20 DTG/ABT (group II) n = 24 BIC/TAF/FTC (group III)
n = 22
Delayed chemotherapy 0 1 0
Dose reduction of chemotherapy 0 1 0
Interruption of chemotherapy 0 0 1

CRC = colorectal cancer

DTG/3TC/TDF = dolutegravir/lamivudine/tenofovir

DTG/ABT = dolutegravir/albuvirtide

BIC/TAF/FTC = bictegravir/tenofovir alafenamide/emtricitabine